Novel Taxanes: Cabazitaxel Case Study

Bouchard, Hervé; Semiond, Dorothée; Vrignaud, Patricia

doi:10.1002/9783527651085.ch13

Cited by 11 publications

(24 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 However, no taxane-based regimen has emerged as being significantly more effective than established treatments. 19 Cabazitaxel is a second-generation taxane developed to overcome resistance to first-generation taxanes, 29 and has shown comparable antitumor activity to docetaxel in docetaxel-sensitive tumor models and increased potency versus docetaxel in taxane-resistant tumor models. 30 In this study, cabazitaxel failed to demonstrate improved efficacy versus topotecan in patients with SCLC that had progressed during or after first-line platinum-based chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy

Evans¹,

Cho

Udud

et al. 2015

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy

Evans¹,

Cho

Udud

et al. 2015

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…Cabazitaxel (Jevtana) is a novel third-generation semisynthetic analog of docetaxel (8,(10)(11)(12). Structurally, cabazitaxel and docetaxel are very similar with the exception of 2 methoxy side chains in cabazitaxel that substitute for hydroxyl groups in docetaxel (Fig.…”

Section: Introductionmentioning

confidence: 99%

“…Cabazitaxel was approved in 2010 as a second-line treatment in men with metastatic castration-resistant prostate cancer that failed docetaxel-containing regimens (17,18). Like paclitaxel and docetaxel, cabazitaxel stabilizes microtubules against cold-induced depolymerization and promotes assembly of tubulin into microtubules (12,14).…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells

Azarenko

Smiyun

Mah

et al. 2014

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Cabazitaxel, a novel chemotherapeutic taxane, is effective against docetaxel-resistant cells and tumors. It is approved for treatment of metastatic hormone-refractory prostate cancer in patients pretreated with docetaxel. Objective responses have been observed in many other cancers, including pretreated metastatic breast cancer. Cabazitaxel and docetaxel share a high degree of structural similarity. The basis for cabazitaxel's efficacy is unclear, and its mechanism has not been described. We compared the effects of cabazitaxel and docetaxel on MCF7 human breast cancer cells expressing fluorescent tubulin. Both drugs inhibited cell proliferation (IC 50s , cabazitaxel, 0.4 AE 0.1 nmol/L, docetaxel, 2.5 AE 0.5 nmol/L) and arrested cells in metaphase by inducing mitotic spindle abnormalities. Drug concentrations required for halfmaximal mitotic arrest at 24 hours were similar (1.9 nmol/L cabazitaxel and 2.2 nmol/L docetaxel). Cabazitaxel suppressed microtubule dynamic instability significantly more potently than docetaxel. In particular, cabazitaxel (2 nmol/L) suppressed the microtubule shortening rate by 59% (compared with 49% for 2 nmol/L docetaxel), the growing rate by 33% (vs. 19%), and overall dynamicity by 83% (vs. 64%). Cabazitaxel was taken up into cells significantly faster than docetaxel, attaining an intracellular concentration of 25 mmol/L within 1 hour, compared with 10 hours for docetaxel. Importantly, after washing, the intracellular cabazitaxel concentration remained high, whereas the docetaxel concentration was significantly reduced. The data indicate that the potency of cabazitaxel in docetaxel-resistant tumors is due to stronger suppression of microtubule dynamics, faster drug uptake, and better intracellular retention than occurs with docetaxel.

show abstract

“…Cabazitaxel is a second-generation, semisynthetic taxane chemotherapy developed to overcome resistance to older taxanes (Bouchard, Semiond, Risse, & Vrignaud, 2013). Cabazitaxel is approved for patients with mCRPC who have progressed on prior docetaxel therapy based on TROPIC, a phase III, randomized, open-label study.…”

Section: Cabazitaxelmentioning

confidence: 99%

Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives

Rama¹,

Pratz

2015

CJON

View full text Add to dashboard Cite

To ensure that patients derive optimal clinical benefit, assessing overall health and proactively managing expected side effects are essential. Treatment sequencing in mCRPC is an important consideration, but clinical data in this area are limited. Despite medical advances in mCRPC, studies have identified other aspects of care in which improvement is needed. Nurses can make major contributions to addressing supportive care needs, which has been shown to improve patient care and outcomes in prostate cancer. Although patient navigation programs have improved coordination of care, inconsistent implementation among centers has been identified for prostate cancer. Greater use of outcome measures can help to identify unmet patient needs.

show abstract

Novel Taxanes: Cabazitaxel Case Study

Cited by 11 publications

References 28 publications

Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy

Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy

Antiproliferative Mechanism of Action of the Novel Taxane Cabazitaxel as Compared with the Parent Compound Docetaxel in MCF7 Breast Cancer Cells

Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives

Contact Info

Product

Resources

About